Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

CEPI has committed $50 million to Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based vaccine against Bundibugyo ebolavirus. The funding supports rapid development of a vaccine candidate targeting BDBV, which is spreading uncontrollably in the Democratic Republic of the Congo. Moderna will conduct laboratory and early human trials under the grant. The effort is part of CEPI's broader initiative to accelerate outbreak response. This marks a significant step in mRNA vaccine deployment for emerging Ebola threats.